Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022.
Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
Passbolt est une application permettant la gestion des identifiants et mot de passe.
Founded in 2010, Hyprevention is a French company that develops, manufactures and sells implantable...
Europea Residences selects the most sumptuous places around the world for you and your family. Disco...
Osimis technology helps clinical teams and medtech professionals optimize the management of their me...
TrustUp.be is a platform that helps individuals to find a reliable professional for small and big jo...
Open Stent Solution
A potential $4 billion market, an unmet clinical need in the field of heart valve disease, 1.8 milli...
European Drone School
European Drone School started in 2016 as the Belgian Drone School, teaching students how to obtain a...
Twistiti developed a unique concept that replaces numbers on the watch, which are usually difficult...
Apaxen is a biotechnology company developing therapeutic anti-inflammatory drugs for the treatment o...
Protect your property and your loved ones with an all-in-one insurance solution!